http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CA-2290537-C
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6420d04b0d68f339771080e32bd0fbc9 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-549 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-549 |
| filingDate | 1998-05-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2007-10-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1f1ce0da8e97dd9904842f829498fae8 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6e30a5393c1ecbe0273c7682f2ca9dd7 |
| publicationDate | 2007-10-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CA-2290537-C |
| titleOfInvention | Use of taurolidine for treatment of leukemias |
| abstract | Taurolidine (taurolin; tauroline; 4,4'-methylenebis(perhydro-1,2,4-thiadiazin 1,1-dioxide) has been found to be an effective agent for treating patients inflicted with monocytic and/or myeloid leukemias through the induction of apoptosis in leukemia cells. Concentrations of taurolidine in the range of 50 to 100 µg/ml induced apoptosis in 75 % of peripheral blood monocytes incubated in culture medium within six hours. Further, 100 µg/ml taurolidine induced apoptosis in 92 % of granulocytes incubated in culture medium within six hours. Taurolidine was also effective in reducing the hypercoagulable state associated with tissue factor expression on leukemia cells, providing a means by which the incidence and degree of severity of coagulopathies associated with tissue factor expression can be reduced in leukemia patients. Preferred therapeutic dosages for treatment of leukemias are from about 10 to about 500 mg/kg body weight. Most preferred is a dose that results in a 200 µg/ml concentration in the plasma, which is typically about 150 mg/kg body weight. |
| priorityDate | 1997-05-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 241.